Andreas

List of Publications by Year
in descending order

106 papers	6,515 citations	94269 37 h-index	66788 78 g-index
120 all docs	120 docs citations	120 times ranked	6847 citing authors

#	Article	IF	Citations
1	Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia, 2015, 29, 2062-2068.	3.3	455
2	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncology, The, 2018, 19, 747-757.	5.1	444
3	Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood, 2009, 114, 5264-5270.	0.6	366
4	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncology, The, 2015, 16, 1691-1699.	5.1	347
5	Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3â€“Internal Tandem Duplication Mutation (SORMAIN). Journal of Clinical Oncology, 2020, 38, 2993-3002.	0.8	335
6	Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia, 2015, 29, 1123-1132.	3.3	248
7	Compassionate use of sorafenib in FLT3-ITDâ€“positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood, 2009, 113, 6567-6571.	0.6	245
8	Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncology, The, 2012, 13, 1035-1044.	5.1	237
9	Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 2017, 31, 2398-2406.	3.3	232
10	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature Medicine, 2018, 24, 282-291.	15.2	216
11	High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia, 2012, 26, 2353-2359.	3.3	208
12	Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia, 2005, 19, 1774-1782.	3.3	203
13	Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia, 2007, 21, 1267-1275.	3.3	200
14	Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood, 2015, 126, 42-49.	0.6	171
15	Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 1429-1435.	0.8	153
16	Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood, 2007, 109, 2147-2155.	0.6	135
17	Interferon-Î±, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood, 2003, 101, 259-264.	0.6	131
18	Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood, 2004, 103, 3480-3489.	0.6	96

#	Article	IF	Citations
19	Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial. Blood, 2018, 132, 661-661.	0.6	87
20	CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood, 2022, 139, 87-103.	0.6	82
21	Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood, 2012, 119, 530-539.	0.6	81
22	PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2017, 52, 317-320.	1.3	81
23	Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia, 2017, 31, 829-836.	3.3	74
24	Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial). Leukemia, 2017, 31, 2523-2525.	3.3	71
25	Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Annals of Hematology, 2015, 94, 2015-2024.	0.8	67
26	Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematology,the, 2018, 5, e161-e169.	2.2	67
27	IRF8 Regulates Acid Ceramidase Expression to Mediate Apoptosis and Suppresses Myelogeneous Leukemia. Cancer Research, 2011, 71, 2882-2891.	0.4	62
28	Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia. Leukemia, 2006, 20, 437-443.	3.3	59
29	Long-term survival of sorafenib-treated FLT3-ITDâ€“positive acute myeloid leukaemia patients relapsingÂafter allogeneic stem cell transplantation. European Journal of Cancer, 2017, 86, 233-239.	1.3	59
30	Determinants for transformation induced by the Axl receptor tyrosine kinase. Oncogene, 1998, 16, 3177-3187.	2.6	53
31	Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia, 2015, 29, 1331-1335.	3.3	51
32	High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia, 2020, 34, 2074-2086.	3.3	50
33	Response to tyrosine kinase inhibitors in myeloid neoplasms associated with <scp>PCM1â€JAK2</scp>, <scp>BCRâ€JAK2</scp> and <scp>ETV6â€ABL1</scp> fusion genes. American Journal of Hematology, 2020, 95, 824-833.	2.0	46
34	Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplantation, 2013, 48, 403-407.	1.3	45
35	Interferon Regulatory Factor-8 Is Indispensable for the Expression of Promyelocytic Leukemia and the Formation of Nuclear Bodies in Myeloid Cells. Journal of Biological Chemistry, 2007, 282, 5633-5640.	1.6	40
36	Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e128-e140.	2.0	40

#	Article	IF	Citations
37	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia, 2021, 35, 2517-2525.	3.3	40
38	NFATc1 as a therapeutic target in FLT3-ITD-positive AML. Leukemia, 2015, 29, 1470-1477.	3.3	39
39	Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region. Nucleic Acids Research, 2005, 33, 6895-6905.	6.5	37
40	Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. Journal of Clinical Oncology, 2017, 35, 175-184.	0.8	36
41	Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. Journal of Cellular Biochemistry, 2002, 86, 642-650.	1.2	35
42	Acid ceramidase of macrophages traps herpes simplex virus in multivesicular bodies and protects from severe disease. Nature Communications, 2020, 11, 1338.	5.8	32
43	Recent Progress On the Role of Axl, A Receptor Tyrosine Kinase, in Malignant Transformation of Myeloid Leukemias. Leukemia and Lymphoma, 1997, 25, 91-96.	0.6	31
44	Interferon a and T-cell responses in chronic myeloid leukemia. Leukemia and Lymphoma, 2005, 46, 167-175.	0.6	31
45	Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitorsâ€"a novel antiproliferative/antiangiogenic strategy in thyroid cancer. Langenbeck's Archives of Surgery, 2006, 391, 589-596.	0.8	30
46	The Combination of MiRNA-196b, LCN2, and TIMP1 is a Potential Set of Circulating Biomarkers for Screening Individuals at Risk for Familial Pancreatic Cancer. Journal of Clinical Medicine, 2018, 7, 295.	1.0	30
47	Maintenance therapy for <i>FLT3-ITD</i>-mutated acute myeloid leukemia. Haematologica, 2021, 106, 664-670.	1.7	30
48	EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. Haematologica, 2020, 105, e228-e231.	1.7	29
49	Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine, 2007, 31, 105-113.	1.1	28
50	Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells. Thrombosis and Haemostasis, 2006, 95, 708-714.	1.8	27
51	FLT3-ITDâ€", but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment. Blood, 2006, 107, 2094-2097.	0.6	26
52	Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). Leukemia, 2020, 34, 2276-2278.	3.3	23
53	Roots of imatinib resistance: A question of self-renewal?. Drug Resistance Updates, 2007, 10, 152-161.	6.5	21
54	Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis. Annals of Hematology, 2014, 93, 279-285.	0.8	21

#	Article	IF	Citations
55	Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. Blood Advances, 2021, 5, 3279-3289.	2.5	21
56	CD82 (KAI1), a member of the tetraspan family, is expressed on early haemopoietic progenitor cells and up-regulated in distinct human leukaemias. British Journal of Haematology, 1999, 107, 494-504.	1.2	20
57	The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial. Blood, 2017, 130, 721-721.	0.6	20
58	Effect of ABCG2 , OCT1 , and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 266-271.	0.2	18
59	Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica, 2019, 104, 955-962.	1.7	18
60	Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study. Blood Advances, 2022, 6, 1394-1405.	2.5	17
61	Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. Journal of Hematology and Oncology, 2022, 15, 60.	6.9	17
62	Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens. Biology of Blood and Marrow Transplantation, 2018, 24, 276-281.	2.0	16
63	Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia. Cancer Research, 2018, 78, 6223-6234.	0.4	16
64	The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). Leukemia, 2021, 35, 2917-2923.	3.3	16
65	Phase I/II Study of the Deacetylase Inhibitor Panobinostat As Maintenance Therapy after an Allogeneic Stem Cell Transplantation in Patients with High-Risk MDS or AML: The Panobest-Trial. Blood, 2015, 126, 4344-4344.	0.6	16
66	IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells. Cancers, 2021, 13, 764.	1.7	14
67	Dose-Reduced Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis. Results from a Multicenter Prospective Trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).. Blood, 2007, 110, 683-683.	0.6	14
68	Nilotinib Vs Nilotinib Plus Pegylated Interferon Î± (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response. Blood, 2019, 134, 495-495.	0.6	13
69	Nuclear factor of activated T-cells, NFATC1, governs FLT3ITD-driven hematopoietic stem cell transformation and a poor prognosis in AML. Journal of Hematology and Oncology, 2019, 12, 72.	6.9	12
70	High Î²-1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusion. OncoImmunology, 2018, 7, e1423169.	2.1	10
71	Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib. Blood, 2016, 128, 4561-4561.	0.6	10
72	Maintaining Low BCR-ABL Signaling Output to Restrict CML Progression and Enable Persistence. Current Hematologic Malignancy Reports, 2014, 9, 9-16.	1.2	9

#	Article	IF	Citations
73	Pathologic Hepatic Contrast-Enhanced Ultrasound Pattern in Patients Undergoing Allogeneic Stem Cell Transplantation. Ultrasound in Medicine and Biology, 2020, 46, 1865-1871.	0.7	9
74	Response: too much BCR-ABL to live on, but too little BCR-ABL to die on?. Blood, 2012, 119, 2965-2966.	0.6	7
75	Value and Diagnostic Accuracy of Ultrasoundâ€Guided Full Core Needle Biopsy in the Diagnosis of Lymphadenopathy: A Retrospective Evaluation of 793 Cases. Journal of Ultrasound in Medicine, 2020, 39, 559-567.	0.8	7
76	Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations â€“ a registry based analysis. Leukemia and Lymphoma, 2021, 62, 1432-1440.	0.6	7
77	Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. Cancers, 2021, 13, 2095.	1.7	7
78	Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia.. Blood, 2009, 114, 2060-2060.	0.6	7
79	Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase. Blood, 2017, 130, 897-897.	0.6	7
80	Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation. Leukemia and Lymphoma, 2015, 56, 2690-2698.	0.6	6
81	Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study. Blood, 2018, 132, 460-460.	0.6	6
82	Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study). Blood, 2008, 112, 565-565.	0.6	6
83	Post-Transplant Maintenance With The Deacetylase Inhibitor Panobinostat In Patients With High-Risk AML Or MDS: Results Of The Phase I Part Of The Panobest Trial. Blood, 2013, 122, 3315-3315.	0.6	6
84	Sorafenib Monotherapy Is Effective In Relapsed and RefractoryFlt3-ITD Positive Acute Myeloid Leukemia, Particularly After Allogenic Stem Cell Transplantation. Blood, 2010, 116, 3314-3314.	0.6	4
85	Monitoring Therapy with Gene Expression Profiling Reveals Physiological Differences in Drug Action. Current Pharmaceutical Design, 2004, 10, 1959-1968.	0.9	4
86	Differential diagnosis of pericardial effusion after stem cell transplantation in acute myeloic leukemia. Herz, 2011, 36, 352-354.	0.4	3
87	Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2149-2156.	1.2	3
88	Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia. Blood, 2018, 132, 1461-1461.	0.6	3
89	Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis. Blood, 2011, 118, 1019-1019.	0.6	3
90	Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia. Leukemia and Lymphoma, 2011, 52, 2031-2035.	0.6	2

#	Article	IF	Citations
91	Outcome of non-mold effective anti-fungal prophylaxis in patients at high-risk for invasive fungal infections after allogenic stem cell transplantation. Leukemia and Lymphoma, 2019, 60, 2056-2061.	0.6	2
92	Reply to S. Fuji. Journal of Clinical Oncology, 2021, 39, 1412-1413.	0.8	2
93	High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels. Blood, 2019, 134, 666-666.	0.6	2
94	Reply to V. Pitini et al. Journal of Clinical Oncology, 2010, 28, e440-e440.	0.8	1
95	EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia. Blood, 2018, 132, 1528-1528.	0.6	1
96	An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission. Blood, 2011, 118, 157-157.	0.6	1
97	BCR-ABL-Induced Transcriptional Repression of the Interferon Regulatory Factor 8 (IRF-8/ICSBP) Leads to Depletion of Plasmocytoid Dendritic Cells (PDC), Which May Contribute to Leukemogenesis in a Murine Model of Chronic Myeloid Leukemia. Blood, 2012, 120, 36-36.	0.6	1
98	Thiotepa-Fludarabine-Treosulfan (TFT) Conditioning for 2nd Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (HCT) from a Second Unrelated Donor in Patients with Acute Myeloid Leukemia (AML) Relapsed after Prior Allogeneic HCT: A Prospective Multicenter Phase II Trial. Blood, 2018, 132, 210-210.	0.6	1
99	Diffuse pneumatosis due to central venous catheterization in a patient with acute graft-versus-host disease. Annals of Hematology, 2007, 86, 767-769.	0.8	0
100	Cloning and characterization of a novel druggable fusion kinase in acute myeloid leukemia. Haematologica, 2020, 105, e395-e398.	1.7	0
101	Adaptive Autocrine Secretion of the Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Mediates Imatinib- and Nilotinib-Resistance in BCR/ABL-Positive Progenitors Via JAK-2/STAT-5 Pathway Activation.. Blood, 2006, 108, 2187-2187.	0.6	0
102	Knockdown of the Nuclear Oncogene SKI Inhibits Flt3-ITD Induced Signaling in 32D - Flt3-ITD Cells.. Blood, 2006, 108, 4491-4491.	0.6	0
103	Chronische myeloische LeukÃmie. , 2014, , 1-11.		0
104	Impact of unbalanced karyotypes at diagnosis on prognosis of CML.. Journal of Clinical Oncology, 2015, 33, 7041-7041.	0.8	0
105	Ten-year survival after randomized comparison of imatinib (IM) 400 mg vs. IM 800 mg vs. IM + IFN vs. IM + Ara C vs. IM after IFN in chronic myeloid leukemia (CML).. Journal of Clinical Oncology, 2017, 35, 7049-7049.	0.8	0
106	Pathological Hepatic Contrast-Enhanced Ultrasound (CEUS) Pattern in Patients Undergoing Allogeneic Stem Cell Transplantation (allo-SCT). Blood, 2018, 132, 3359-3359.	0.6	0